In Taiwan, gefitinib, erlotinib, and afatinib had been reimbursed in first-line treatment for advanced lung adenocarcinoma harboring EGFR mutation in 2011, 2013, and 2014, respectively. This evidence concerns the gene EGFR and lung adenocarcinoma.